The Potential Value & Impact of Biosimilars | BioEngage from Amgen Biosimilars

Biosimilars cost savings: a valuable impact on healthcare costs

Biosimilars are expected to have a robust impact on lowering healthcare costs

  • Biosimilars are expected to save the EU up to $44B in healthcare costs by 2020.1
  • Over the next 5–10 years in the US, it is estimated that biosimilars can save the healthcare system approximately $150B.2

The value of biosimilars in the marketplace

  • Biosimilars offer the opportunity for system-wide cost savings3
  • The introduction of biosimilars can provide headroom for greater investment in innovator products3
  • Biosimilars can provide more treatment options to patients with serious illnesses3

References: 1. Inside Sources. Europe demonstrates benefits of a strong biosimilars marketplace. Accessed October 29, 2019. 2. The Center For Biosimilars. Biosimilars market is ripe for cost savings. Accessed October 29, 2019. 3. The Biosimilars Council. Biosimilars in the United States. Accessed October 29, 2019.